- lung
cancer (
NSCLC), or non-small-cell lung carcinoma, is any type of
epithelial lung
cancer other than small-cell lung
cancer (SCLC).
NSCLC accounts for...
-
overactive NTRK (<1% of
NSCLC) by
entrectinib or larotrectinib;
active RET (around 1% of
NSCLC) by selpercatinib.
People whose NSCLC is not
targetable by...
- of ALK-rearranged
NSCLC harbour the EML4-ALK fusion,
although as of 2020, over 92
fusion partners have been
discovered in ALK+
NSCLC. For each
fusion partner...
-
medication used to
treat urothelial carcinoma, non-small cell lung
cancer (
NSCLC),
small cell lung
cancer (SCLC),
hepatocellular carcinoma and
alveolar soft...
- (SCLC) and non-small cell lung
cancer (
NSCLC). This is done
because of
differing responses to treatment—
NSCLC is
comparatively less
sensitive to chemotherapy...
- prescription-only drug used for the
treatment of non-small cell lung
cancer (
NSCLC). It was
developed by
Novartis and
received FDA
approval for use in April...
-
patients with EGFR T790M mutation—positive non-small-cell lung
cancer (
NSCLC) who have
progressed on or
after other EGFR TKI therapy.
Shirley M, Keam...
- G12C–Mutated
NSCLC". ascopost.com.
Retrieved March 4, 2022.
Kristi Rosa (January 10, 2022). "Sotorasib
Approved in
Europe for KRAS G12C–Mutated
Advanced NSCLC"....
-
growth factor receptor-mutated
locally advanced or
metastatic non-squamous
NSCLC in
patients who have
progressed past
tyrosine kinase inhibitor therapy,...
-
carcinoma (
NSCLC). It
belongs to the
tyrosine kinase inhibitor family of medications. It is
taken by mouth. It is
mainly used to
treating cases of
NSCLC that...
